Evaluation of CYP2C9 Activity

Hadassah Medical Organization1,200 enrolled

Overview

The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9. The purpose of the present study is: 1. To confirm the use of phenytoin metabolic ratio as a marker of CYP2C9 activity 2. To correlate phenytoin metabolic ratio with CYP2C9 genotype 3. To study the frequency distribution of CYP2C9 activity in-vivo

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

1,200

Conditions

Healthy

Interventions

Phenytoin single dose (300 mg)DRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age range of 20-50 years old * Absence of significant disease states Exclusion Criteria: * The presence of significant disease states * The use of drugs (including birth control pills)

Locations (1)

Hadassah Medical Organization

Jerusalem, Israel

RECRUITING

Outcomes

Primary Outcomes

Correlation between phenytoin metabolic ratio and CYP2C9 genotype

Time frame: 24 hours

Frequency distribution of phenytoin metabolic ratio in the population

Time frame: 24 hours

Central Contacts

Yoseph Caraco, MD

CONTACT

00 972 2 6778584 caraco@hadassah.org.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.